Development of bispecific antibodies with enhanced neutralization activity against tested SARS-CoV-2 Omicron subvariants

1

The study focuses on bispecific antibodies (bsAbs) designed to enhance neutralization against SARS-CoV-2 Omicron subvariants.
2

A fully human antibody phage-display library, Omni-Mab, was utilized to identify antibodies specific to SARS-CoV-2.
3

Lead bsAbs R3-1a-1/R4-1a-10 and R4-21/R4-1a-51 exhibited superior binding and neutralizing efficacy compared to traditional monoclonal antibodies.
4

The research highlights the potential of bsAbs to overcome limitations of monoclonal antibody cocktails in combating viral mutations.
5

The study demonstrates that engineered bsAbs maintain activity against both Omicron and selected non-Omicron pseudovirus strains.

Frontiers In Immunology

by Ching-Hsuan Hsu, Ting-Yi Chang, Ya-Min Chang, Shin-Han Lin, Tzu-Ning Chen, Keng-Hao Hsu, Jhong-Jhe You
June 17, 2026

1